MX359147B - Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato. - Google Patents
Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato.Info
- Publication number
- MX359147B MX359147B MX2015007578A MX2015007578A MX359147B MX 359147 B MX359147 B MX 359147B MX 2015007578 A MX2015007578 A MX 2015007578A MX 2015007578 A MX2015007578 A MX 2015007578A MX 359147 B MX359147 B MX 359147B
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- ylethynyl
- pyridazin
- imidazo
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261736543P | 2012-12-12 | 2012-12-12 | |
| US201261737007P | 2012-12-13 | 2012-12-13 | |
| US201361788208P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/074571 WO2014093579A2 (en) | 2012-12-12 | 2013-12-12 | Crystalline forms of 3-(imidazo[1,2-b] pyridazin-3-ylethynyl)-4-methyl-n-(4-[(4-methylpiperazin-1-yl) methyl]-3-(trifluoromethyl)phenyl)benzamide and its mono hydrochloride salt |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015007578A MX2015007578A (es) | 2016-03-21 |
| MX359147B true MX359147B (es) | 2018-09-17 |
Family
ID=50929140
Family Applications (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015007578A MX359147B (es) | 2012-12-12 | 2013-12-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3-iletinil)-4-me til-n-(4-[ (4-metilpiperazin-1-il) metil]-3-(trifluorometil) fenil) benzamida y su sal de monoclorhidrato. |
| MX2018010998A MX391445B (es) | 2012-12-12 | 2013-12-12 | Formas cristalinas de 3-(imidazol[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002255A MX2021002255A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002254A MX2021002254A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002253A MX2021002253A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002257A MX2021002257A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002261A MX2021002261A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002258A MX2021002258A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002264A MX2021002264A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002256A MX2021002256A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002259A MX2021002259A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
Family Applications After (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018010998A MX391445B (es) | 2012-12-12 | 2013-12-12 | Formas cristalinas de 3-(imidazol[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il)metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002255A MX2021002255A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002254A MX2021002254A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002253A MX2021002253A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002257A MX2021002257A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002261A MX2021002261A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002258A MX2021002258A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002264A MX2021002264A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002256A MX2021002256A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
| MX2021002259A MX2021002259A (es) | 2012-12-12 | 2015-06-12 | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. |
Country Status (9)
| Country | Link |
|---|---|
| US (9) | US9493470B2 (enExample) |
| JP (4) | JP6447508B2 (enExample) |
| CN (2) | CN115043843A (enExample) |
| CA (3) | CA3167093A1 (enExample) |
| CL (1) | CL2015001643A1 (enExample) |
| HK (1) | HK1218878A1 (enExample) |
| MX (11) | MX359147B (enExample) |
| NZ (1) | NZ709648A (enExample) |
| WO (2) | WO2014093579A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2761180T3 (es) | 2005-12-23 | 2020-05-19 | Ariad Pharma Inc | Compuestos bicíclicos de heteroarilo |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之三唑酮化合物 |
| CA3167093A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
| EP3016954B1 (en) * | 2013-07-04 | 2018-10-31 | Sandoz AG | Crystalline forms of ponatinib hydrochloride |
| CN104496995A (zh) * | 2014-01-06 | 2015-04-08 | 广东东阳光药业有限公司 | 制备3-乙炔基咪唑并[1,2-b]哒嗪的方法 |
| CN110291081B (zh) * | 2016-12-15 | 2023-01-31 | 阿瑞雅德制药公司 | 作为c-kit抑制剂的苯并咪唑化合物 |
| US10221184B2 (en) | 2017-01-20 | 2019-03-05 | Apicore Us Llc | Polymorphs of ponatinib hydrochloride |
| CA3067271A1 (en) | 2017-06-20 | 2018-12-27 | Apotex Inc. | Crystalline forms of ponatinib hydrochloride |
| DK3774844T3 (da) * | 2018-04-02 | 2023-04-03 | Stealth Biotherapeutics Inc | Krystallinske dipeptider, der er anvendelige i syntese af elamipretid |
| EP3781568A1 (en) | 2018-06-22 | 2021-02-24 | Johnson Matthey Public Limited Company | Form of ponatinib |
| MX2021005007A (es) | 2018-11-01 | 2021-07-21 | Syros Pharmaceuticals Inc | Inhibidores de cinasa 7 dependiente de ciclina (cdk7). |
| WO2020223235A1 (en) | 2019-04-29 | 2020-11-05 | Incyte Corporation | Mini-tablet dosage forms of ponatinib |
| CN111004240B (zh) * | 2019-12-13 | 2020-12-01 | 山东铂源药业有限公司 | 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5099067A (en) | 1988-08-05 | 1992-03-24 | Northwestern University | Use of ammonium formate as a hydrogen transfer reagent for reduction of chiral nitro compounds with retention of configuration |
| CN1177840C (zh) | 1999-11-08 | 2004-12-01 | 先灵公司 | 制备n-(4-羟基苯基)-n′-(4′-氨基苯基)-哌嗪的方法 |
| HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| DE10021246A1 (de) | 2000-04-25 | 2001-10-31 | Schering Ag | Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel |
| IL159811A0 (en) | 2001-07-13 | 2004-06-20 | Neurogen Corp | Heteroaryl substituted fused bicyclic heteroaryl compounds as gabaa receptor ligands |
| TW200418466A (en) | 2002-11-06 | 2004-10-01 | Smithkline Beecham Corp | Chemical compounds |
| GB0230089D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
| TW200529849A (en) | 2003-11-28 | 2005-09-16 | Novartis Ag | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
| AU2004296242A1 (en) | 2003-12-05 | 2005-06-23 | Biovitrum Ab | Improved synthesis of 2-substituted adenosines |
| JP2007517007A (ja) | 2003-12-24 | 2007-06-28 | アストラゼネカ アクチボラグ | Tie2(TEK)活性を持つピリミジン |
| ES2309591T3 (es) | 2003-12-24 | 2008-12-16 | Astrazeneca Ab | Pirimidinas con actividad tie2(tek). |
| EA011930B1 (ru) | 2004-04-07 | 2009-06-30 | Лаборатуар Сероно Са | Карбоновые кислоты |
| EA200700243A1 (ru) | 2004-07-14 | 2007-08-31 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения гепатита с |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| GB0502418D0 (en) | 2005-02-05 | 2005-03-16 | Astrazeneca Ab | Compounds |
| US20080194552A1 (en) | 2005-03-31 | 2008-08-14 | Astrazeneca Ab | Aminopyrimidine Derivatives With Tie2 Inhibiting Activity |
| WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| JP5321061B2 (ja) | 2005-08-11 | 2013-10-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 不飽和複素環誘導体 |
| ES2761180T3 (es) * | 2005-12-23 | 2020-05-19 | Ariad Pharma Inc | Compuestos bicíclicos de heteroarilo |
| CN101389338B (zh) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | 双环杂芳基化合物 |
| JP5273037B2 (ja) | 2006-05-08 | 2013-08-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | アセチレン性ヘテロアリール化合物 |
| EA200870515A1 (ru) | 2006-05-08 | 2009-06-30 | Ариад Фармасьютикалз, Инк. | Моноциклические гетероарильные соединения |
| EP2107054A1 (en) | 2008-04-01 | 2009-10-07 | Università Degli Studi Di Milano - Bicocca | Antiproliferative compounds and therapeutic uses thereof |
| WO2010124047A1 (en) | 2009-04-23 | 2010-10-28 | Wyeth Llc | Bisaryl alkynylamides as negative allosteric modulators of metabotropic glutamate receptor 5 (mglur5) |
| US8329724B2 (en) | 2009-08-03 | 2012-12-11 | Hoffmann-La Roche Inc. | Process for the manufacture of pharmaceutically active compounds |
| EA201290255A1 (ru) * | 2009-10-30 | 2013-04-30 | Ариад Фармасьютикалз, Инк. | Способы и композиции для лечения рака |
| EA201391486A1 (ru) | 2011-04-07 | 2014-09-30 | Ариад Фармасьютикалз, Инк. | Способы и композиции для лечения болезни паркинсона |
| CA2832483A1 (en) | 2011-04-07 | 2012-10-11 | Ariad Pharmaceuticals, Inc. | Methods and compositions for treating neurodegenerative diseases |
| US20150105377A1 (en) | 2012-04-25 | 2015-04-16 | Ariad Pharmaceuticals, Inc. | Methods and Compositions for RAF Kinase Mediated Diseases |
| CA3167093A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
-
2013
- 2013-05-09 CA CA3167093A patent/CA3167093A1/en active Pending
- 2013-05-09 CA CA2815506A patent/CA2815506C/en active Active
- 2013-05-09 CA CA3022250A patent/CA3022250A1/en not_active Abandoned
- 2013-12-12 WO PCT/US2013/074571 patent/WO2014093579A2/en not_active Ceased
- 2013-12-12 MX MX2015007578A patent/MX359147B/es active IP Right Grant
- 2013-12-12 WO PCT/US2013/074585 patent/WO2014093583A2/en not_active Ceased
- 2013-12-12 CN CN202210369530.8A patent/CN115043843A/zh active Pending
- 2013-12-12 US US14/651,577 patent/US9493470B2/en active Active
- 2013-12-12 JP JP2015547524A patent/JP6447508B2/ja active Active
- 2013-12-12 HK HK16106954.3A patent/HK1218878A1/zh unknown
- 2013-12-12 NZ NZ709648A patent/NZ709648A/en unknown
- 2013-12-12 MX MX2018010998A patent/MX391445B/es unknown
- 2013-12-12 CN CN201380072027.5A patent/CN105188701A/zh active Pending
-
2015
- 2015-06-12 MX MX2021002255A patent/MX2021002255A/es unknown
- 2015-06-12 CL CL2015001643A patent/CL2015001643A1/es unknown
- 2015-06-12 MX MX2021002254A patent/MX2021002254A/es unknown
- 2015-06-12 MX MX2021002253A patent/MX2021002253A/es unknown
- 2015-06-12 MX MX2021002257A patent/MX2021002257A/es unknown
- 2015-06-12 MX MX2021002261A patent/MX2021002261A/es unknown
- 2015-06-12 MX MX2021002258A patent/MX2021002258A/es unknown
- 2015-06-12 MX MX2021002264A patent/MX2021002264A/es unknown
- 2015-06-12 MX MX2021002256A patent/MX2021002256A/es unknown
- 2015-06-12 MX MX2021002259A patent/MX2021002259A/es unknown
-
2016
- 2016-11-02 US US15/341,898 patent/US10125136B2/en active Active
-
2018
- 2018-07-09 JP JP2018129624A patent/JP7042175B2/ja active Active
- 2018-09-28 US US16/146,143 patent/US10662197B2/en active Active
-
2020
- 2020-05-22 US US16/881,790 patent/US11279705B2/en active Active
-
2021
- 2021-05-12 US US17/318,772 patent/US11192896B2/en active Active
- 2021-05-12 US US17/318,832 patent/US11192897B2/en active Active
- 2021-05-12 US US17/318,876 patent/US11384086B2/en active Active
- 2021-05-12 US US17/318,677 patent/US11192895B2/en active Active
- 2021-12-15 JP JP2021203538A patent/JP7352841B2/ja active Active
-
2023
- 2023-02-27 US US18/175,272 patent/US20240083902A1/en not_active Abandoned
- 2023-09-19 JP JP2023150905A patent/JP2023179498A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002258A (es) | Formas cristalinas de 3-(imidazo[1,2-b] piridazin-3- iletinil)-4-metil-n-(4-[(4-metilpiperazin-1-il) metil]-3-(trifluorometil)fenil) benzamida y su sal de monoclorhidrato. | |
| ZA202109164B (en) | 4 - imidazopyridazin- 1 -yl-benzamides and 4 - imidazotriazin- 1 - yl - benzamides as btk- inhibitors | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| NZ631112A (en) | Crystalline bromodomain inhibitors | |
| IN2014DN09352A (enExample) | ||
| EA201691242A1 (ru) | Фармацевтические композиции, содержащие azd9291 | |
| IN2014DN09348A (enExample) | ||
| MX2013014788A (es) | Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos. | |
| MX394588B (es) | Composición farmacéutica. | |
| IN2014DN09347A (enExample) | ||
| PH12018501331A1 (en) | Crystalline forms of thienopyrimidine compound | |
| PH12017501832A1 (en) | Stabilized pharmaceutical composition | |
| EA201500446A1 (ru) | Фармацевтическая композиция для снижения уровня n-оксида триметиламина | |
| MX2014002141A (es) | Carboxamidas de n-(5-cicloalquil - o 5-heterociclil-)-piridin-3-il o. | |
| IN2013CH01248A (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GD | Licence granted | ||
| FG | Grant or registration |